Citations

Showing 10 of 108094 citations.

A novel method for handling Missing Not at Random Data in the electronic health records
Shen, Xinpeng , Ma, Sisi , Vemuri, Prashanthi , Simon, György , Vemuri, Prashanthi , Caraballo, Pedro J.

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 21-26

10.1109/ichi54592.2022.00015 Get It

Creating Computer Vision Models for Respiratory Status Detection
Chaudri, Jamil, Do, Quan T.

Mayo Clinic

2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1350-1353

10.1109/embc48229.2022.9871978 | PMID 36086309 Get It

Neural Transformers for Intraductal Papillary Mucosal Neoplasms (IPMN) Classification in MRI images
Salanitri, Federica Proietto , Bellitto, Giovanni , Irmakci, Ismail , Wallace, Michael B. , Bolan, Candice W. , Engels, Megan , Hoogenboom, Sanne, Wallace, Michael B , Palazzo, Simone , Aldinucci, Marco , Bağcı, Ulaş , Giordano, D., Spampinato, Concetto

Mayo Clinic

2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 475-479

10.1109/embc48229.2022.9871547 | PMID 36085787 Get It

Deep Learning Method for Hip Knee Ankle Angle Prediction on Postoperative Full-Limb Radiographs of Total Knee Arthroplasty Patients
Yan, Shi , Ramazanian, Taghi , Chaudhary, Vipin , Kremers, Hilal Maradit

Mayo Clinic

2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 5070-5073

10.1109/embc48229.2022.9870936 | PMID 36086644 Get It

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ali, Haris , Dunbar, Andrew , Elshoury, Amro, Gundabolu, Krishna , Jain, Tania , Jamieson, Catriona , Kaesberg, Paul, Madanat, Yazan F. , McMahon, Brandon , Nadiminti, Kalyan , Pardanani, Animesh , Rein, Lindsay , Salit, Rachel B. , Stein, Brady L. , Vachhani, Pankit , Wadleigh, Martha , Wall, Sarah , Ward, Dawn C., Bergman, Mary Anne, Hochstetler, Cindy L., Madanat, Yazan , Gerds, Aaron T. , Gotlib, Jason , Bose, Prithviraj , George, Tracy I. , Hexner, Elizabeth O. , Hobbs, Gabriela , Kuykendall, Andrew , Mohan, Sanjay , Oh, Stephen T. , Podoltsev, Nikolai , Talpaz, Moshe

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 1033-1062

10.6004/jnccn.2022.0046 | PMID 36075392 Get It

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.
Quality-of-Life Outcomes After Modified Subtotal Petrosectomy With Ear Canal Closure for Chronic Otitis Media
Macielak, Robert J. , Lohse, Christine M. , Tuchscherer, Amy M., Carlson, Matthew L. , Tuchscherer, Amy M.

Mayo Clinic

Otology & Neurotology | September 8, 2022 | Volume: 43 | Issue: 9 | Pages: e1013-e1019

10.1097/mao.0000000000003673 | PMID 36075106 Get It

Objective To assess quality-of-life (QoL) outcomes after modified subtotal petrosectomy with ear canal closure (mSTP) for chronic otitis media. Study Design Survey study. Setting Tertiary referral center. Patients Patients with chronic otitis media. Interventions mSTP. Main Outcome Measures Survey results from enrolled patients on the validated disease-specific Chronic Ear Survey (CES) and Chronic Otitis Media Outcome Test-15 (COMOT-15) regarding their current state of health and, if surgery was performed within 3 years of enrollment, their state of health before mSTP. Results A total of 23 patients were studied, including 19 who underwent surgery within 3 years of enrollment. Postoperatively, mean total CES scores were 80 and COMOT-15 scores were 41, with a higher CES and a lower COMOT-15 indicating better QoL. There were statistically significant improvements after mSTP in the CES activity restriction (25% difference; p = 0.008), symptom (17% difference; p = 0.007), and medical resource (13% difference; p = 0.03) domain and total (18% difference; p = 0.006) scores. In addition, there were statistically significant improvements in the COMOT-15 ear symptom (−22% difference; p < 0.001) domain and total (−16% difference; p = 0.01) scores; however, improvements in the hearing function and mental health domains did not achieve statistical significance. Postoperative COMOT-15 total scores were significantly better for patients who underwent aural rehabilitation compared to those who did not (−17% difference; p < 0.001). Conclusion Modified subtotal petrosectomy with ear canal closure is a useful intervention for patients with recalcitrant chronic otitis media, offering improved QoL in appropriately selected patients. Aural rehabilitation, when feasible, provides the potential for further QoL improvement.
Evaluation of mCODE Coverage in EHR: a Scoping Review of Cancer Natural Language Processing
Wang, Liwei , Ruan, Xiaoyang , Mai, Michelle , Wang, Nan , Xu, Hua , Fu, Sunyang , Wen, Andrew , He, Huan , Liu, Sijia , Moon, Sungrim , Riaz, Irbaz Bin , Yang, Ping , Warner, Jeremy L. , Liu, Hongfang

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 517-518

10.1109/ichi54592.2022.00094 Get It

Evaluation of Document-Level Identification of Pulmonary Nodules in Radiology Reports Using FLAIR Natural Language Processing Framework
Qian, Ray , Fu, Sunyang , Liu, Hongfang

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 515-516

10.1109/ichi54592.2022.00093 Get It

FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
Abdelrahman, Amro M. , Goenka, Ajit H. , Leiting, Jennifer L. , Merrell, Kenneth W. , Hallemeier, Christopher L. , Haddock, Michael G. , Smoot, Rory L. , Nagorney, David M. , Kendrick, Michael L. , Truty, Mark J. , Smoot, Rory L , Abdelrahman, Amro M , Alva‐Ruiz, Roberto , Yonkus, Jennifer A. , Graham, Rondell P. , Thiels, Cornelius A. , Hallemeier, Christopher Leigh , Warner, Susanne G. , Grotz, Travis E. , Tran, Nguyen H., Wee, Wen , Cleary, Sean P. , McWilliams, Robert R. , Hálfdánarson, Þorvarður R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 1023-1032.e3

10.6004/jnccn.2022.7041 | PMID 36075389 Get It

Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly predicts response, and biochemical (CA 19-9) markers are not useful (nonsecretors/nonelevated) in many patients. Pathologic response highly predicts survival post-NAT, but is only known postoperatively. Because metabolic imaging (FDG-PET) reveals primary tumor viability, this study aimed to evaluate our experience with preoperative FDG-PET in patients with BR/LA PDAC in predicting NAT response and survival. Methods: We reviewed all patients with resected BR/LA PDAC who underwent NAT with FDG-PET within 60 days of resection. Pre- and post-NAT metabolic (FDG-PET) and biochemical (CA 19-9) responses were dichotomized in addition to pathologic responses. We compared post-NAT metabolic and biochemical responses as preoperative predictors of pathologic responses and recurrence-free survival (RFS) and overall survival (OS). Results: We identified 202 eligible patients. Post-NAT, 58% of patients had optimization of CA 19-9 levels. Major metabolic and pathologic responses were present in 51% and 38% of patients, respectively. Median RFS and OS times were 21 and 48.7 months, respectively. Metabolic response was superior to biochemical response in predicting pathologic response (area under the curve, 0.86 vs 0.75; P <.001). Metabolic response was the only univariate preoperative predictor of OS (odds ratio, 0.25; 95% CI, 0.13–0.40), and was highly correlated ( P =.001) with pathologic response as opposed to biochemical response alone. After multivariate adjustment, metabolic response was the single largest independent preoperative predictor ( P <.001) for pathologic response (odds ratio, 43.2; 95% CI, 16.9–153.2), RFS (hazard ratio, 0.37; 95% CI, 0.2–0.6), and OS (hazard ratio, 0.21; 95% CI, 0.1–0.4). Conclusions: Among patients with post-NAT resected BR/LA PDAC, FDG-PET highly predicts pathologic response and survival, superior to biochemical responses alone. Given the poor ability of anatomic imaging or biochemical markers to assess NAT responses in these patients, FDG-PET is a preoperative metric of NAT efficacy, thereby allowing potential therapeutic alterations and surgical treatment decisions. We suggest that FDG-PET should be an adjunct and recommended modality during the NAT phase of care for these patients.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Armstrong, Deborah K. , Barroilhet, Lisa , Chitiyo, Viola C., Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , McHale, Michael , Miller, David S. , Percac‐Lima, Sanja , Remmenga, Steven W., Schorge, John O., Vargas, Roberto , Hendrickson, Andrea Wahner, Werner, Theresa L. , Dwyer, Mary A., Hang, Lisa E., Miller, David S , Alvarez, Ronald D. , Backes, Floor , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Chitiyo, Viola, DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Leiserowitz, Gary S. , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen , Stewart, Daphne B. , Thaker, Premal H. , Zsíros, Emese

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 972-980

10.6004/jnccn.2022.0047 | PMID 36075393 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.